Azathioprine suppresses ezrin-radixin-moesin-dependent T cell-APC conjugation through inhibition of Vav guanosine exchange activity on rac proteins

Journal of Immunology

Volumn 176, Issue 1, 2006, Pages 640-651

  Poppe, Daniela ^a   Tiede, Imke ^a   Fritz, Gerhard ^a   Becker, Christoph ^a   Bartsch, Brigitte ^a   Wirtz, Stefan ^a   Strand, Dennis ^a   Tanaka, Shinya ^b   Galle, Peter R ^a   Bustelo, Xosé R ^c   Neurath, Markus F ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CD4 ANTIGEN; CYTOKINE; EZRIN; GAMMA INTERFERON; GUANOSINE DIPHOSPHATE; GUANOSINE TRIPHOSPHATASE; GUANOSINE TRIPHOSPHATE; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2; MERCAPTOPURINE; MOESIN; PROTEIN CDC42; RAC PROTEIN; RADIXIN; RAP PROTEIN; RAS PROTEIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; THIOGUANOSINE;

ANTIGEN PRESENTING CELL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME ACTIVATION; ENZYME ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE CULTURE; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; PROTEIN PURIFICATION; T LYMPHOCYTE; WESTERN BLOTTING;

EID: 29644444216     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.176.1.640     Document Type: Article

References (65)

1. Elion, G. B. 1993. The George Hitchings and Gertrude Elion Lecture: the pharmacology of azathioprine. Ann. NY Acad. Sci. 685: 400-407.
2. Candy, S., J. Wright, M. Gerber, G. Adams, M. Gerig, and R. Goodman. 1995. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 37: 674-678.
3. 1988. Double-masked trial of azathioprine in multiple sclerosis: British and Dutch Multiple Sclerosis Azathioprine Trial Group. Lancet 2: 179-186.
4. McGeown, M., J. F. Douglas, R. A. Donaldson, C. M. Hill, J. A. Kennedy, W. G. Loughridge, and D. Middleton. 1988. Ten-year results of renal transplantation with azathioprine and prednisolone as only immunosuppression. Lancet 1: 983-985.
5. Lennard, L. 1992. The clinical pharmacology of 6-mercaptopurine. Eur. J. Clin. Pharmacol. 43: 329-335.
6. Present, D. H., B. I. Korelitz, N. Wisch, J. L. Glass, D. B. Sachar, and B. S. Pasternack. 1980. Treatment of Crohn's disease with 6-mercaptopurine: a long-term randomized, double-blind study. N. Engl. J. Med. 302: 981-987.
7. Sandborn, W. J., W. J. Tremaine, D. C. Wolf, S. R. Targan, C. A. Sninsky, L. R. Sutherland, S.B. Hanauer, J. W. McDonald, B. G. Feagan, R. N. Fedorak, et al. 1999. Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. Gastroenterology 117: 527-535.
8. Fraser, A. G., T. R. Orchard, and D. P. Jewell. 2002. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 50: 485-489.
9. Lewis, J. D., J. S. Schwartz, and G. R. Lichtenstein. 2000. Azathioprine for maintenance of remission in Crohn's disease: benefits outweigh the risk of lymphoma. Gastroenterology 118: 1018-1024.
10. D'Haens, G., K. Geboes, E. Ponette, F. Penninckx, and P. Rutgeerts. 1997. Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease. Gastroenterology 112: 1475-1481.
11. Bean, R. H. D. 1962. The treatment of chronic active ulcerative colitis with 6-mercaptopurine. Med. J. Aust. 2: 592-593.
12. Maltzman, J. S., and G. A. Koretzky. 2003. Azathioprine: old drug, new actions. J. Clin. Invest. 111: 1122-1124.
13. Quemeneur, L., L. M. Gerland, M. Flacher, M. Ffrench, J. P. Revillard, and L. Genestier. 2003. Differential control of cell cycle, proliferation, and survival of primary T lymphocytes by purine and pyrimidine nucleotides. J. Immunol. 170: 4986-4995.
14. Cuffari, C., E. G. Seidman, S. Latour, and Y. Theoret. 1996. Quantification of 6-thioguanine in peripheral blood leukocyte DNA in Crohn's disease patients on maintenance 6-mercaptopurine therapy. Can. J. Physiol. Pharmacol. 74: 580-585.
15. + T lymphocytes. J. Clin. Invest. 111: 1133-1145.
16. Prieto-Sanchez, R. M., and X. R. Bustelo. 2003. Structural basis for the signaling specificity of RhoG and Rac1 GTPases. J. Biol. Chem. 278: 37916-37925.
17. Bustelo, X. R. 2002. Knocked out by Rho/Rac T-cell biology. Histol. Histopathol. 17: 871-875.
18. Li, B., H. Yu, W.-P. Zheng, R. Voll, S. Na, A. W. Roberts, D. A. Williams, R. J. Davis, S. Ghosh, and R. A. Flavell. 2000. Role of the guanosine triphosphate Rac2 in T helper 1 cell differentiation. Science 288: 2219-2222.
19. Gomez, M., V. Tybulewicz, and D. A. Cantrell. 2000. Control of pre T cell proliferation and differentiation by the GTPase Rac1. Nat. Immunol. 1: 348-352.
20. Joneson, T., and D. Bar-Sagi. 1999. Suppression of Ras-induced apoptosis by the Rac GTPase. Mol. Cell. Biol. 19: 5892-5901.
21. Woodside, D. G., D. K. Wooten, T. K. Teague, Y. J. Miyamoto, E. G. Caudell, T. Udagawa, B. F. Andruss, and B. W. McIntyre. 2003. Control of T lymphocyte morphology by the GTPase Rho. BMC Cell Biol. 4: 2-12.
22. Cannon, J. L., C. M. Labno, G. Bosco, A. Seth, M. H. McGavin, K. A. Siminovitch, M. K. Rosen, and J. K. Burkhardt. 2001. Wasp recruitment to the T cell:APC contact site occurs independently of Cdc42 activation. Immunity 15: 249-259.
23. Atreya, R., J. Mudter, S. Finotto, J. Müllberg, T. Jostock, S. Wirtz, M. Schütz, B. Bartsch, M. Holtmann, C. Becker, et al. 2000. Blockade of IL-6 trans signaling suppresses T cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn's disease and experimental colitis in vivo. Nat. Med. 6: 583-588.
24. Becker, C., S. Wirtz, M. Blessing, J. Pirhonen, D. Strand, O. Bechthold, J. Frick, P. R. Galle, I. Autenrieth, and M. F. Neurath. 2003. Constitutive p40 promoter activation and IL-23 production in the terminal ileum mediated by dendritic cells. J. Clin. Invest. 112: 693-706.
25. Tharaux, P. L., R. C. Bukoski, P. N. Rocha, S. D. Crowley, P. Ruiz, P., C. Nataraj, D. N. Howell, K. Kaibuchi, R. F. Spurney, and T. M. Coffman. 2003. Rho kinase promotes alloimmune responses by regulating the proliferation and structure of T cells. J. Immunol. 171: 96-105.
26. Crespo, P., K. E. Schuebel, A. A. Ostrom, J. S. Gutkind, and X. R. Bustelo. 1997. Phosphotyrosine-dependent activation of Rac-1 GDP/GTP exchange by the vav proto-oncogene product. Nature 385: 169-172.
27. Movilla, N., and X. R. Bustelo. 1999. Biological and regulatory properties of Vav-3, a new member of the Vav family of oncoproteins. Mol. Cell. Biol. 19: 7870-7885.
28. Schuebel, K. E., N. Movilla, J. L. Rosa, and X. R. Bustelo. 1998. Phosphorylation-dependent and constitutive activation of Rho proteins by wild-type and oncogenic Vav-2. EMBO J. 17: 6608-6621.
29. Salazar-Fontana, L. I., V. Barr, L. E. Samelson, and B. E. Bierer. 2003. CD28 engagement promotes actin polymerization through the activation of the small Rho GTPase Cdc42 in human T cells. J. Immunol. 171: 2225-2232.
30. Westerberg, L., G. Greicius, S. B. Snapper, P. Aspenstrom, and E. Severinson. 2001. Cdc42, Rac1, and the Wiskott-Aldrich syndrome protein are involved in the cytoskeletal regulation of B lymphocytes. Blood 98: 1086-1094.
31. Roumier, A., J. C. Olivo-Marin, M. Arpin, F. Michel, M. Martin, P. Mangeat, O. Acuto, A. Dautry-Varsat, and A. Alcover. 2001. The membrane-microfilament linker ezrin is involved in the formation of the immunological synapse and in T cell activation. Immunity 15: 715-728.
32. Delon, J., K. Kaibuchi, and R. N. Germain. 2001. Exclusion of CD43 from the immunological synapse is mediated by phosphorylation-regulated relocation of the cytoskeletal adaptor moesin. Immunity 15: 691-701.
33. Allenspach, E. J., P. Cullinan, J. Tong, Q. Tang, A. G. Tesciuba, J. L. Cannon, S. M. Takahashi, R. Morgan, J. K. Burkhardt, and A. I. Sperling. 2001. ERM-dependent movement of CD43 defines a novel protein complex distal to the immunological synapse. Immunity 15: 739-750.
34. Katagiri, K., M. Hattori, N. Minato, and T. Kinashi. 2002. Rap1 functions as a key regulator of T-cell and antigen-presenting cell interactions and modulates T-cell responses. Mol. Cell. Biol. 22: 1001-1015.
35. Katagiri, K., A. Maeda, M. Shimonaka, and T. Kinashi. 2003. RAPL, a Rap1-binding molecule that mediates Rap1-induced adhesion through spatial regulation of LFA-1. Nat. Immunol. 4: 741-748.
36. Sebzda, E., M. Bracke, T. Tugal, N. Hogg, and D. A. Cantrell. 2002. Rap1 A positively regulates T cells via integrin activation rather than inhibiting lymphocyte signaling. Nat. Immunol. 3: 251-258.
37. Shimonaka, M., K. Katagiri, T. Nakayama, N. Fujita, T. Tsuruo, O. Yoshie, and T. Kinashi. 2003. Rap1 translates chemokine signals to integrin activation, cell polarization, and motility across vascular endothelium under flow. J. Cell Biol. 161: 417-427.
38. Sims, T. N., M. L. Dustin. 2002. The immunological synapse: integrins take the stage. Immunol. Rev. 186: 100-117.
39. Matsuguchi, T., R. C. Inhorn, N. Carlesso, G. Xu, B. Druker, and J. D. Griffin. 1995. Tyrosine phosphorylation of p95Vav in myeloid cells is regulated by GM-CSF, IL-3 and steel factor and is constitutively increased by p210BCR/ABL. EMBO J. 14: 257-265.
40. Evans, G. A., O. M. Howard, R. Erwin, and W. L. Farrar. 1993. Interleukin-2 induces tyrosine phosphorylation of the vav proto-oncogene product in human T cells: lack of requirement for the tyrosine kinase lck. Biochem. J. 294: 339-342.
41. Hehner, S. P., M. Li-Weber, M. Giaisi, W. Droge, P. H. Krammer, and M. L. Schmitz. 2000. Vav synergizes with protein kinase Cθ to mediate IL-4 gene expression in response to CD28 costimulation in T cells. J. Immunol. 164: 3829-3836.
42. Faure, S., L. I. Salazar-Fontana, M. Semichon, V. L. Tybulewicz, G. Bismuth, A. Trautmann, R. N. Germain, and J. Delon. 2004. ERM proteins regulate cytoskeleton relaxation promoting T cell-APC conjugation. Nat. Immunol. 5: 272-279.
43. Tybulewicz, V. L., L. Ardouin, A. Prisco, and L. F. Reynolds. 2003. Vav1: a key signal transducer downstream of the TCR. Immunol. Rev. 192: 42-52.
44. Hornstein, I., A. Alcover, and S. Katzav. 2004. Vav proteins, masters of the world of cytoskeleton organization. Cell. Signal. 16: 1-11.
45. Fujikawa, K., A. V. Miletic, F. W. Alt, R. Faccio, T. Brown, J. Hoog, J. Fredericks, S. Nishi, S. Mildiner, S. L. Moores, et al. 2003. Vav1/2/3-null mice define an essential role for Vav family proteins in lymphocyte development and activation but a differential requirement in MAPK signaling in T and B cells. J. Exp. Med. 198: 1595-1608.
46. Zakaria, S., T. S. Gomez, D. N. Savoy, S. McAdam, M. Turner, R. T. Abraham, and D. D. Billadeau. 2004. Differential regulation of TCR-mediated gene transcription by Vav family members. J. Exp. Med. 199: 429-434.
47. Aghazadeh, B., W. E. Lowry, X. Y. Huang, and M. K. Rosen. 2000. Structural basis for relief of autoinhibition of the Db1 homology domain of proto-oncogene Vav by tyrosine phosphorylation. Cell 102: 625-633.
48. Turner, M., and D. D. Billadeau. 2002. VAV proteins as signal integrators for multi-subunit immune-recognition receptors. Nat. Rev. Immunol. 2: 476-486.
49. Raab, M., S. Pfister, and C. E. Rudd. 2001. CD28 signaling via VAV/SLP-76 adaptors: regulation of cytokine transcription independent of TCR ligation. Immunity 15: 921-933.
50. Piccolella, E., F. Spadaro, C. Ramoni, B. Marinari, A. Costanzo, M. Levrero, L. Thomson, R. T. Abraham, and L. Tuosto. 2003. Vav-1 and the IKKα subunit of IκB kinase functionally associate to induce NF-κB activation in response to CD28 engagement. J. Immunol. 170: 2895-2903.
51. Marinari, B., A. Costanzo, A. Viola, F. Michel, G. Mangino, O. Acuto, M. Levrero, E. Piccolella, and L. Tuosto. 2002. Vav cooperates with CD28 to induce NF-κB activation via a pathway involving Rac-1 and mitogen-activated kinase kinase 1. Eur. J. Immunol. 32: 447-456.
52. Turner, M., P. J. Mee, A. E. Walters, M. E. Quinn, A. L. Mellor, R. Zamoyska, and V. L. Tybulewicz. 1997. A requirement for the Rho-family GTP exchange factor Vav in positive and negative selection of thymocytes. Immunity 7: 451-460.
53. Tarakhovsky, A., M. Turner, S. Schaal, P. J. Mee, L. P. Duddy, K. Rajewsky, and V. L. Tybulewicz. 1995. Defective antigen receptor-mediated proliferation of B and T cells in the absence of Vav. Nature 374: 467-470.
54. Zhang, R., F. W. Alt, L. Davidson, S. H. Orkin, and W. Swat. 1995. Defective signalling through the T- and B-cell antigen receptors in lymphoid cells lacking the vav proto-oncogene. Nature 374: 470-473.
55. Röllinghoff, M., J. Schrader, and H. Wagner. 1973. Effect of azathioprine and cytosine arabinoside on humoral and cellular immunity in vitro. Clin. Exp. Immunol. 15: 261-269.
56. Abdou, N. I., B. Zweiman, and S. R. Casella. 1973. Effects of azathioprine therapy on bone marrow-dependent and thymus-dependent cells in man. Clin. Exp. Immunol. 13: 55-64.
57. Cuffari, C., D. Y. Li, J. Mahoney, Y. Barnes, and T. M. Bayless. 2004. Peripheral blood mononuclear cell DNA 6-thioguanine metabolite levels correlate with decreased interferon-γ production in patients with Crohn's disease on AZA therapy. Dig. Dis. Sci. 49: 133-137.
58. Neurath, M. F., I. Fuss, B. L. Kelsall, E. Stuber, and W. Strober. 1995. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J. Exp. Med. 182: 1281-1290.
59. Neurath, M. F., S. Finotto, and L. H. Glimcher. 2002. The role of Th1/Th2 polarization in mucosal immunity. Nat. Med. 8: 567-573.
60. Bouma, G., and W. Strober. 2003. The immunological and genetic basis of inflammatory bowel disease. Nat. Rev. Immunol. 3: 521-533.
61. Tanaka, Y., T. So, S. Lebedeva, M. Croft, and A. Altman. 2005. Impaired IL-4 and c-Maf expression and enhanced Th1 cell development in Vav1-deficient mice. Blood. 106: 1286-1295.
62. Aihara, M., K. Dobashi, K. Iizuka, T. Nakazawa, and M. Mori. 2004. Effect of Y-27632 on release of cytokines from peripheral T cells in asthmatic patients and normal subjects. Int. Immunopharmacol. 4: 557-561.
63. Pickard, K. M., A. R. Bremner, J. N. Gordon, and T. T. MacDonald. 2004. Microbial-gut interactions in health and disease. Immune responses. Best Pract. Res. Clin. Gastroenterol. 18: 271-285.
64. Hanauer, S. B., B. I. Korelitz, P. Rutgeerts, M. A. Peppercorn, R. A. Thisted, R. D. Cohen, and D. H. Present. 2004. Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology 127: 723-729.
65. Reedquist, K. A., and J. L. Bos. 1998. Costimulation through CD28 suppresses T cell receptor-dependent activation of the Ras-like small GTPase Rap1 in human T lymphocytes. J. Biol. Chem. 273: 4944-4949.